Successful treatment with enfortumab–vedotin of metastatic signet ring cell cancer expressing nectin-4 and originating from the bladder

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:IJU Case Reports vol. 7, no. 2 (Mar 2024), p. 110
Prif Awdur: Aoki, Maria
Awduron Eraill: Naiki, Taku, Naiki-Ito, Aya, Morikawa, Toshiharu, Matsuyama, Nayuka, Torii, Koei, Kato, Taiki, Maruyama, Tetsuji, Inaguma, Shingo, Yasui, Takahiro
Cyhoeddwyd:
John Wiley & Sons, Inc.
Pynciau:
Mynediad Ar-lein:Citation/Abstract
Full Text + Graphics
Full Text - PDF
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

MARC

LEADER 00000nab a2200000uu 4500
001 2933872849
003 UK-CbPIL
022 |a 2577-171X 
024 7 |a 10.1002/iju5.12678  |2 doi 
035 |a 2933872849 
045 2 |b d20240301  |b d20240331 
100 1 |a Aoki, Maria  |u Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
245 1 |a Successful treatment with enfortumab–vedotin of metastatic signet ring cell cancer expressing nectin-4 and originating from the bladder 
260 |b John Wiley & Sons, Inc.  |c Mar 2024 
513 |a Journal Article Case Study 
520 3 |a IntroductionAs an aggressive adenocarcinoma phenotype, primary signet ring cell carcinoma of the urinary bladder is an extremely rare variant. The prognosis of metastatic signet ring cell carcinoma of the urinary bladder is extremely poor and the clinical course for its specific pathogenesis remains unelucidated.Case presentationA 64-year-old Japanese male patient was diagnosed with invasive urothelial carcinoma with glandular differentiation of a signet ring cell–type with pT4aN0M0, and he was eventually diagnosed with metastatic signet ring cell carcinoma of the urinary bladder. He was initially responsive to systemic combination induction chemotherapy of S-1 and cisplatin followed by avelumab switch maintenance therapy; however, signet ring cell carcinoma of the urinary bladder relapse occurred in the pathological findings of a biopsy from the right thigh. Immunohistochemical analysis of this specimen identified strong positive staining for nectin-4 and, following enfortumab–vedotin treatment, the patient showed a good response.ConclusionWe thus describe a rare case of metastatic signet ring cell carcinoma of the urinary bladder with nectin-4 expression diagnosed by a biopsy of a metastatic site. 
651 4 |a Japan 
653 |a Patients 
653 |a Medical prognosis 
653 |a Metastasis 
653 |a Antibodies 
653 |a Musculoskeletal system 
653 |a Cancer therapies 
653 |a Magnetic resonance imaging 
653 |a Biopsy 
653 |a Edema 
653 |a Body fat 
653 |a Conflicts of interest 
653 |a Bladder cancer 
653 |a Informed consent 
653 |a Urological surgery 
653 |a Chemotherapy 
653 |a Case reports 
653 |a Monoclonal antibodies 
653 |a Targeted cancer therapy 
653 |a Immunotherapy 
700 1 |a Naiki, Taku  |u Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
700 1 |a Naiki-Ito, Aya  |u Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
700 1 |a Morikawa, Toshiharu  |u Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
700 1 |a Matsuyama, Nayuka  |u Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
700 1 |a Torii, Koei  |u Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
700 1 |a Kato, Taiki  |u Department of Urology, Nagoya City University East Medical Center, Nagoya, Japan 
700 1 |a Maruyama, Tetsuji  |u Department of Urology, Nagoya City University East Medical Center, Nagoya, Japan 
700 1 |a Inaguma, Shingo  |u Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
700 1 |a Yasui, Takahiro  |u Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan 
773 0 |t IJU Case Reports  |g vol. 7, no. 2 (Mar 2024), p. 110 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/2933872849/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch 
856 4 0 |3 Full Text + Graphics  |u https://www.proquest.com/docview/2933872849/fulltextwithgraphics/embedded/75I98GEZK8WCJMPQ?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/2933872849/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch